Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IRTCNASDAQ:NARINASDAQ:PRCTNASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIRTCiRhythm Technologies$100.42+2.7%$106.55$55.92▼$128.52$3.15B1.36464,316 shs107,265 shsNARIInari Medical$79.97$78.86$36.73▼$79.99$4.68B1.02986,853 shsN/APRCTPROCEPT BioRobotics$57.96+3.4%$70.60$45.56▼$103.81$3.18B1.06720,368 shs317,479 shsTNDMTandem Diabetes Care$19.18+5.5%$31.74$17.64▼$53.69$1.27B1.451.48 million shs638,459 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIRTCiRhythm Technologies-3.85%-3.57%-8.53%+13.12%-6.67%NARIInari Medical0.00%0.00%+0.11%+43.86%+94.53%PRCTPROCEPT BioRobotics-2.71%-7.51%-15.11%-37.21%+11.66%TNDMTandem Diabetes Care-3.14%-2.88%-45.76%-44.34%-36.50%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIRTCiRhythm Technologies1.4977 of 5 stars3.41.00.00.02.30.00.6NARIInari Medical1.5689 of 5 stars2.13.00.00.01.33.30.6PRCTPROCEPT BioRobotics2.9811 of 5 stars3.43.00.00.03.12.50.6TNDMTandem Diabetes Care4.4791 of 5 stars4.31.00.04.94.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIRTCiRhythm Technologies 2.82Moderate Buy$119.7319.22% UpsideNARIInari Medical 2.14Hold$68.00-14.97% DownsidePRCTPROCEPT BioRobotics 2.86Moderate Buy$94.2962.69% UpsideTNDMTandem Diabetes Care 2.61Moderate Buy$45.38136.57% UpsideCurrent Analyst Ratings BreakdownLatest TNDM, NARI, PRCT, and IRTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/5/2025TNDMTandem Diabetes CareMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$45.00 ➝ $22.003/4/2025TNDMTandem Diabetes CareCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.00 ➝ $24.003/3/2025TNDMTandem Diabetes CareThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$42.00 ➝ $24.003/3/2025TNDMTandem Diabetes CareWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$38.00 ➝ $22.002/28/2025TNDMTandem Diabetes CareBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$60.00 ➝ $53.002/28/2025TNDMTandem Diabetes CareSanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$35.00 ➝ $25.002/27/2025TNDMTandem Diabetes CareRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$65.00 ➝ $55.002/27/2025TNDMTandem Diabetes CareRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$37.00 ➝ $33.002/26/2025PRCTPROCEPT BioRoboticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$105.00 ➝ $95.002/26/2025PRCTPROCEPT BioRoboticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$105.00 ➝ $90.002/26/2025TNDMTandem Diabetes CareCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$63.00 ➝ $63.00(Data available from 3/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIRTCiRhythm Technologies$591.84M5.33N/AN/A$6.85 per share14.66NARIInari Medical$493.63M9.48$0.09 per share906.95$8.07 per share9.91PRCTPROCEPT BioRobotics$224.50M14.15N/AN/A$5.56 per share10.42TNDMTandem Diabetes Care$940.20M1.36N/AN/A$4.81 per share3.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIRTCiRhythm Technologies-$123.41M-$3.64N/AN/AN/A-19.14%-118.83%-11.34%5/1/2025 (Estimated)NARIInari Medical-$1.64M-$1.35N/A727.00N/A-13.68%-10.09%-6.60%4/28/2025 (Estimated)PRCTPROCEPT BioRobotics-$105.90M-$1.76N/AN/AN/A-50.07%-38.57%-26.06%5/7/2025 (Estimated)TNDMTandem Diabetes Care-$222.61M-$1.46N/AN/AN/A-14.84%-44.19%-11.99%5/1/2025 (Estimated)Latest TNDM, NARI, PRCT, and IRTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/25/2025Q4 2024PRCTPROCEPT BioRobotics-$0.34-$0.35-$0.01-$0.35$66.79 million$68.24 million2/20/2025Q4 2024IRTCiRhythm Technologies-$0.29$0.01+$0.30-$0.04$158.30 million$164.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIRTCiRhythm TechnologiesN/AN/AN/AN/AN/ANARIInari MedicalN/AN/AN/AN/AN/APRCTPROCEPT BioRoboticsN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIRTCiRhythm Technologies9.006.276.12NARIInari MedicalN/A1.771.40PRCTPROCEPT BioRobotics0.216.025.07TNDMTandem Diabetes Care1.292.902.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIRTCiRhythm TechnologiesN/ANARIInari Medical90.98%PRCTPROCEPT BioRobotics89.46%TNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipIRTCiRhythm Technologies0.68%NARIInari Medical10.60%PRCTPROCEPT BioRobotics17.40%TNDMTandem Diabetes Care2.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIRTCiRhythm Technologies1,79031.41 million31.09 millionOptionableNARIInari Medical80058.54 million52.34 millionOptionablePRCTPROCEPT BioRobotics43054.82 million43.10 millionOptionableTNDMTandem Diabetes Care2,40066.47 million64.23 millionOptionableTNDM, NARI, PRCT, and IRTC HeadlinesRecent News About These CompaniesConnor Clark & Lunn Investment Management Ltd. Purchases 242,965 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)March 14 at 4:54 AM | marketbeat.comTandem Diabetes Care (NASDAQ:TNDM) Stock Price Up 6.1% Following Insider Buying ActivityMarch 13 at 10:24 AM | marketbeat.comOptimistic Buy Rating for Tandem Diabetes Care Amid Attractive Valuation and Growth PotentialMarch 13 at 2:33 AM | tipranks.comTandem Diabetes Care (NASDAQ:TNDM) Trading Up 6.1% Following Insider Buying ActivityMarch 13 at 1:56 AM | americanbankingnews.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) COO Acquires $190,948.56 in StockMarch 12 at 7:28 PM | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) COO Buys $190,948.56 in StockMarch 12 at 5:57 AM | insidertrades.comVictory Capital Management Inc. Decreases Stock Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)March 12 at 3:34 AM | marketbeat.comTandem Diabetes COO buys $191K in common stockMarch 11 at 11:28 PM | markets.businessinsider.comReasons to Hold TNDM Stock in Your Portfolio for NowMarch 11 at 9:46 AM | zacks.comTandem Diabetes Care (NASDAQ:TNDM) Reaches New 52-Week Low - What's Next?March 11 at 4:26 AM | marketbeat.comTandem Diabetes Care: A Buy Rating Backed by Growth Potential and Valuation OpportunityMarch 10, 2025 | tipranks.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Sold by Oppenheimer & Co. Inc.March 9, 2025 | marketbeat.comTandem Diabetes Care (NASDAQ:TNDM) Cut to Equal Weight at Morgan StanleyMarch 8, 2025 | americanbankingnews.comTandem Diabetes Care (NASDAQ:TNDM) Cut to "Equal Weight" at Morgan StanleyMarch 6, 2025 | marketbeat.comTandem Diabetes Care (NASDAQ:TNDM) Cut to "Neutral" at CitigroupMarch 6, 2025 | americanbankingnews.comMorgan Stanley Downgrades Tandem Diabetes Care (TNDM)March 6, 2025 | msn.comTandem Diabetes downgraded to Equal Weight from Overweight at Morgan StanleyMarch 5, 2025 | markets.businessinsider.comTandem Diabetes Care (NASDAQ:TNDM) Hits New 1-Year Low - Here's What HappenedMarch 5, 2025 | marketbeat.comThe Goldman Sachs Group Has Lowered Expectations for Tandem Diabetes Care (NASDAQ:TNDM) Stock PriceMarch 5, 2025 | americanbankingnews.comTandem Diabetes Care (NASDAQ:TNDM) Trading Down 5.5% After Analyst DowngradeMarch 5, 2025 | americanbankingnews.comBernstein downgrades Tandem Diabetes on market share loss concernsMarch 4, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTNDM, NARI, PRCT, and IRTC Company DescriptionsiRhythm Technologies NASDAQ:IRTC$100.42 +2.65 (+2.71%) As of 02:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.Inari Medical NASDAQ:NARI$79.97 0.00 (0.00%) As of 02/19/2025Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.PROCEPT BioRobotics NASDAQ:PRCT$57.96 +1.93 (+3.44%) As of 02:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.Tandem Diabetes Care NASDAQ:TNDM$19.18 +1.00 (+5.50%) As of 02:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Deal With Archer Aviation Keeps AI’s Future in Focus D-Wave Quantum Stock Jumps on "Quantum Supremacy" News Is a Bottom Finally Forming in Rocket Lab Stock? Intel Stock Surges on New CEO – The Real Story Runs Deeper AMD Stock: Can the PC Refresh Cycle Spark a Rally? Ramaco Resources Pins Hopes on Coal's Untapped Potential Nu Holdings: Is Brazil’s Fintech Leader a Buy at This Discount? Beyond a Market Correction, Moves to Make Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
